tapebrief
UHS · Q4 2025

UHS · Q1 2026 Earnings

Cautious

Universal Health Services

Reported April 28, 2026

30-second summary

UHS posted Q1 FY2026 revenue of $4.495B (+9.6% YoY) and non-GAAP EPS of $5.62, with acute same-facility revenue per adjusted admission at +6.3% reported (+4.9% ex ~$30M of prior-period Nevada supplemental program benefit) and behavioral patient days at +1.6%. Management reiterated the full-year guide unchanged (revenue $18.417-$18.789B, adj EPS $22.64-$24.52) despite the Q1 FY2026 outperformance, explicitly flagging that exchange declines "will steepen" through the year, and announced a Talkspace acquisition that reframes behavioral from inpatient capacity build to an end-to-end virtual-through-residential continuum.

Headline numbers

EPS

Q1 FY2026

$5.62

Revenue

Q1 FY2026

$4.50B

+9.6% YoY

Free cash flow

Q1 FY2026

$0.18B

Operating margin

Q1 FY2026

11.2%

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$4.50B+9.6%$4.49B+0.2%
EPS$5.62—$5.88-4.4%
Operating margin11.2%—11.5%-30bps
Free cash flow$0.18B———

Guidance

UnitedHealth Group reiterates full-year FY2026 guidance despite strong Q1 results, with revenue and EPS ranges unchanged as management flags continued steepening of exchange declines and moderation in wage pressures.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ1 FY2026Implied ~$4.1B (from 7.1% growth vs FY2025 $17.365B annual / 4 quarters base)$4.495BAbove implied quarterly guide; YoY +9.6%Met
Adjusted EPS (non-GAAP)Q1 FY2026Implied ~$5.90 (from $23.58 midpoint / 4 quarters)$5.62In-line with quarterly run-rate expectationsMet

Reaffirmed unchanged this quarter: EPS Guidance (non-GAAP) ($22.64–$24.52 (midpoint $23.58)), Revenue Guidance ($18.417–$18.789 billion (midpoint $18.603B, +7.1% YoY)), Adjusted EBITDA net of NCI ($2.641–$2.789 billion (midpoint +4.8% YoY))

Segment KPIs

Q1 FY2026
SegmentQ1 FY2026YoY
Acute Care Hospital Services$2.61B+10.7%
Behavioral Health Care Services$1.882B+8.2%

Other KPIs

Q1 FY2026
SegmentQ1 FY2026
Adjusted Admissions (Acute Care, same facility)0.0%
Adjusted Patient Days (Acute Care, same facility)+0.8%
Revenue Per Adjusted Admission (Acute Care, same facility)+6.3%
Adjusted Admissions (Behavioral Health, same facility)+1.2%
Adjusted Patient Days (Behavioral Health, same facility)+1.6%
Revenue Per Adjusted Admission (Behavioral Health, same facility)+6.2%
EBITDA net of NCI Margin14.5%
Adjusted EBITDA net of NCI Margin14.4%

Management tone

Narrative arc: Q2 FY2025 cliff sizing → Q3 FY2025 bullish reframe on DC/Cedar Hill → Q4 FY2025 conservative FY2026 anchor with named headwinds → Q1 FY2026 strategic pivot via Talkspace.

Three quarters ago behavioral growth was framed as an inpatient-bed-capacity problem; two quarters ago management introduced the Thousand Branches outpatient buildout as the organic answer; last quarter Thousand Branches deployment was acknowledged as "slower than initially expected"; this quarter management bought the answer. The verbatim Talkspace framing — "create the industry's first end-to-end continuum of behavioral health care services that is strongly aligned to the demand trends and preferences of the market overall" — converts a multi-year organic buildout into an immediate platform play. The Morgan Stanley exchange made the pivot explicit: 1,000 branches has been state-by-state slow, Talkspace was "opportunistic, not driven by 1,000 branches." This is a tacit admission that the organic outpatient thesis was not progressing fast enough.

AI commentary moved from sidebar to operating model. Two quarters ago AI was named in Q&A as an unquantified offset lever to 2028+ Medicaid reductions; last quarter it remained qualitative; this quarter management disclosed "eight different use cases of AI solutions into our revenue cycle operations that are now yielding significant benefit on a go-forward basis" with specific reference to denial management and incremental revenue dollars. Mark explicitly tied this work to revenue cycle efficiency keeping pace with payers — converting AI from a 2028+ defensive narrative into a FY2026 P&L contributor.

Volume framing softened further from Q4 FY2025. This quarter the language shifted to "same facility growth to be more balanced between volume and pricing as the year progresses" — i.e., pricing is doing the work today and volume needs to catch up later. Q1 FY2026 behavioral patient days at +1.6% and acute admissions at 0.0% reflect the soft start. The hedging language "too early to project the longer-term financial impact of the 2026 initiatives" on Talkspace is paired with this volume softness — the strategic acquisition is being positioned to bear the growth burden the organic story has not delivered.

The Wolfe Research exchange surfaced a credibility tension. The analyst's math implied a ~5-6% core decline in Q1 FY2026 after stripping DPP comparison effects, weather, and flu; management did not dispute the calculation, instead pivoting to maintained full-year guidance confidence. That management did not contest a specifically-quantified core decline figure — and the most evasive topic of the call was core-growth reconciliation — is the cleanest signal that the reiterated FY2026 guide is being defended on faith in H2 catch-up rather than Q1 FY2026 evidence.

Recurring themes management leaned on this quarter:

Strategic shift toward end-to-end behavioral health continuum via Talkspace acquisitionAI deployment at scale with tangible operational and financial benefitsVolume headwinds from seasonal/weather factors expected to normalizeWage pressure moderation in behavioral segmentPricing strength offsetting volume softness in Q1Capital deployment prioritizing organic growth, acquisitions, and shareholder returns

Risks management surfaced:

Health insurance exchange member attrition and premium payment sustainability ($75M full-year pre-tax impact expected)Seasonal volume weakness and winter weather impact (estimated 200 bps in acute, 40-50 bps in behavioral)Weaker flu and respiratory activity dampening volumesCalifornia nurse staffing ratio implementation (June 1 deadline) operational executionTalkspace integration execution and synergy realization timelines

Q&A highlights

Anne Hines · Mizuho

Asked about bad debt reserve trends given Medicaid disenrollment and ACA subsidy expiration, and whether guidance assumes deterioration in copay/deductible collectability.

Management noted HICS volume declined in Q1 but recorded additional reserves for patients who may lose coverage due to missed premium payments. They maintained the $75 million negative estimate for HICS subsidy expiration impact and saw only slight increases in uninsured and Medicare volumes with decreases in Medicaid. Attributed ability to keep pace with payer pressure to technology and revenue cycle investments.

$75 million estimated impact from HICS subsidies expiringAdditional reserve recorded in Q1 for HICS patients expected to lose coverageSlight increase in uninsured volumesSlight decrease in Medicaid utilization

Matthew Gilmore · KeyBank

Asked what drove stronger-than-expected pricing in Q1 and what's behind expected moderation, plus follow-up on professional fee trends, particularly in radiology.

Management attributed stronger pricing to lower flu volumes (higher patient acuity mix) and healthy increases in acute service lines (cardiology, orthopedics, neurology). For professional fees, they indicated guidance assumes single-digit inflation, dealing with hospital-based physician pressure through competitive RFPs and reducing locums usage.

Single-digit professional fee inflation expected, potentially high single digitsSignificant lower flu component in Q1 vs. prior year increased acuityHealthy pricing increases in cardiology, orthopedics, neurologyStrategy includes more RFPs and reduced locums physician usage

Justin Wake · Wolf Research

Asked about core growth math, specifically questioning whether core EBITDA ex-DPP headwinds appears to show approximately 5-6% decline and what might explain this given management's 5% core growth guidance.

Management acknowledged difficulty verifying the analyst's calculation but did not dispute the math. They reiterated that Q1 difficulties (DPP comparison, flu, weather) were anticipated and included in guidance, and emphasized belief they can achieve stated 5% core growth for full year despite Q1 below that target.

Acknowledged analyst calculation suggests ~5-6% core decline in Q1 excluding DPP and headwindsMaintained confidence in full-year 5% core growth guidanceQ1 difficulties (DPP, flu, weather) were expected and included in guidance

Ben Hendricks · RBC Capital Markets

Asked about HICS volume decline (5% observed vs. 25-30% expected for year) and whether Q1 results informed any changes to full-year HICS loss of coverage assumptions.

Management clarified that 5% observed decline in Q1 HICS volumes was offset by reserves for patients later deemed uninsured, implying true decline closer to low double digits (10-12%). They maintained confidence in 25-30% loss of coverage estimate for full year but acknowledged continued learning needed and noted the number may be achieved later in year.

5% observed HICS volume decline in Q1Reserves imply low double-digit true decline (10-12%)Maintained 25-30% loss of coverage estimate for full yearAcknowledged continued dynamics and learning expected for another quarter or more

Craig Hettenbach · Morgan Stanley

Asked about the Talkspace acquisition strategy, how the 1,000 branches outpatient initiative is progressing, and what confidence management has in single-digit earnings multiples in a few years.

Management indicated 1,000 branches deployment has been slower than expected due to state-by-state variations but remains ongoing. Talkspace was opportunistic, not driven by 1,000 branches, and represents a multi-year growth story. They expressed confidence in single-digit multiples based on Talkspace's own growth trajectory and synergies management believes it can add through combined resources.

1,000 branches deployment slower than initially expectedTalkspace acquisition driven by opportunistic offer, not 1,000 branches resultsConfidence in single-digit earnings multiple 'a few years from now'Talkspace on 'great growth path' itself; management expects to add to those achievements

Answers to last quarter's watch list

Q1 FY2026 behavioral adjusted patient days. Came in at +1.6%, with management noting ~40-50bps weather drag. Adjusted admissions at +1.2%. Management's response — that growth will become "more balanced between volume and pricing as the year progresses" — defers the inflection rather than demonstrating it.
Continue monitoring
ACA exchange volume erosion — actual vs. the embedded 25-30% decline assumption. Q1 FY2026 observed decline was 5%, with reserves implying low double-digit (10-12%) underlying erosion. Management maintained the 25-30% full-year coverage loss estimate and the $75M pre-tax impact, with explicit guidance that declines "will steepen." Erosion is running below the assumed pace in Q1 FY2026 — neither a clear validation nor a guide cut trigger.
Continue monitoring
Acute same-facility revenue per adjusted admission run-rate. Landed at +6.3% reported, +4.9% ex ~$30M Nevada prior-period DPP benefit. Management attributed the underlying strength to flu-light acuity mix plus revenue cycle improvements (now linked to 8 deployed AI use cases) and expects pricing to moderate as the year progresses.
Resolved positively
California behavioral staffing ramp ahead of June 1 effective date. Management noted continued moderation in behavioral wage pressures (Q1 FY2026 wage growth ~6% YoY vs. 7-8% in 2025) and reiterated that the company remains on track with the assumptions contemplated in the 2026 outlook for the nurse staffing ratio requirements. This supports the cost-side framing but does not directly quantify the staffing-ratio operational ramp.
Continue monitoring
Q1 FY2026 capex pace against the $950M-$1.1B FY2026 envelope. Q1 FY2026 capex of $217M tracks slightly below straight-line pace; capex typically ramps through year. FCF of $0.185B (4.1% margin) is consistent with that profile.
Continue monitoring
Any new state DPP approvals or supplemental program renewals. No new state DPP approvals named this quarter. Management indicated the pending Florida 2025 program is "likely to be approved" (estimated ~$50M benefit when recognized) while California renewal is "much less certain." The Talkspace acquisition is the named capital action; supplemental program expansion was not.
Continue monitoring

What to watch into next quarter

Whether the FY2026 revenue/EPS guide is raised at Q2 FY2026. Q1 FY2026 delivered +9.6% YoY revenue against a +7.1% FY guide. Holding the guide flat through Q2 FY2026 would imply management sees genuine H2 deceleration; raising would confirm Q1 FY2026 was the underwriting tell.

Behavioral same-facility adjusted patient days trajectory. Q1 FY2026 came in at +1.6%. Continued sub-+2% prints would force a Talkspace-as-growth-rescue narrative.

ACA exchange volume — does the steepening actually arrive? Management said declines "will steepen" through the year. Q1 FY2026 ran below the 25-30% pace at low double digits. A Q2 FY2026 print accelerating toward 20%+ erosion validates the embedded $75M; flatter erosion implies guidance contingency upside.

Talkspace deal close timing and any initial integration metric. Management hedged "we plan to share more details about the impact of the transaction after closing." A Q2 FY2026 close with disclosed cross-referral pilot metrics or virtual-acuity offering rollout would convert the strategic narrative into operating evidence; further hedging signals execution risk.

Acute pricing run-rate — does the ex-DPP +4.9% hold? Management explicitly expects moderation as flu-acuity mix normalizes. A Q2 FY2026 print at or above +5% on a clean basis would suggest the revenue cycle / AI uplift is structurally additive; a sharp step down confirms Q1 FY2026 was acuity-mix driven.

Core growth bridge in Q2 FY2026 disclosure. The Wolfe Research exchange exposed a credibility gap — management would not validate the ~5-6% core decline math. Q2 FY2026 disclosure that explicitly walks DPP, weather, flu, and exchange contributions would defuse the issue; continued high-level framing extends the skepticism.

Florida DPP approval timing and sizing. Management flagged the pending 2025 Florida program as "likely to be approved" with a current ~$50M benefit estimate that "could be measurably higher." Recognition timing will move quarterly comparisons.

Sources

  1. UHS Q1 FY2026 press release, exhibit 99.1: https://www.sec.gov/Archives/edgar/data/352915/000119312526183643/uhs-ex99_1.htm
  2. UHS Q1 FY2026 earnings conference call Q&A (exchanges cited above)
  3. UHS Q4 FY2025, Q3 FY2025, Q2 FY2025 Tapebrief briefs for prior guide and watch-list comparison

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.